Israel
Industry
BMI View: While Israel has historically been a cheap and effective site for clinical trials, it is becoming increasingly expensive compared to emerging markets and it also cannot compete...
2011-11-29Industry
BMI View: Our view that industrial action in Israel would result in an increase in public healthcare expenditure has played out. The government is promising an additional ILS2.7bn (US$764mn)...
2011-11-10Industry
BMI View: We remain positive about Teva Pharmaceutical's short- and medium-term future as the patent cliff approaches and austerity measures and rational prescription increases generic...
2011-11-03Industry
BMI View: The street protests in Israel have greater political and economic implications for the country's future than healthcare provision specifically, despite it being one of the...
2011-08-16Industry
BMI View: Teva's Q211 results are unimpressive but expected given the company's poor Q111 performance. However, BMI remains positive about the company's long-term future as austerity...
2011-07-28Industry
BMI View: Israel claims to have a very efficient healthcare system that means it does not need to spend as much of its GDP on healthcare. In truth, the government's fiscal austerity...
2011-05-04Companies
BMI View: Teva Pharmaceutical Industries continues to favour inorganic growth from mergers and acquisitions (M&A) over in-house research and development (R&D). However, large...
2011-05-03Industry
BMI View: Drugmakers who have moved into emerging markets more slowly than many of their competitors will look to mergers, acquisitions and joint ventures (JVs) with established distributors...
2011-03-28
